Recce Pharmaceuticals gets up to $85M R&D tax incentive for global programs
Recce Pharmaceuticals (ASX:RCE), a developer of a new class of synthetic anti-infectives, has received an Advanced Overseas Finding from the Australian Department of Industry, Science and Resources










